Clinical Trials

recruiting PHASE3 Neurology NCT05980949

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease (ADEPT-3)

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026…

Sponsor: Karuna Therapeutics

View Trial ClinicalTrials.gov ↗

recruiting PHASE3 Neurology NCT05511363

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease (ADEPT-1)

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse…

Sponsor: Karuna Therapeutics

View Trial ClinicalTrials.gov ↗

recruiting Neurology NCT04991831

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson’s Disease

The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.

Sponsor: InSightec

View Trial ClinicalTrials.gov ↗

recruiting Neurology NCT05123443

Longitudinal Assessment of Iron Rims in MS Lesions

In multiple sclerosis (MS), the presence of white matter lesions surrounded by a rim of iron is suggested to signify a more severe disease course. Iron rim lesions can be…

Sponsor: Nottingham University Hospitals NHS Trust

View Trial ClinicalTrials.gov ↗

recruiting NA Neurology NCT07452562

Hesperidin RCT in MS

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of…

Sponsor: Swansea University

View Trial ClinicalTrials.gov ↗

recruiting PHASE2 Neurology NCT07282574

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab. After the end of the double-blind period, an…

Sponsor: Hoffmann-La Roche

View Trial ClinicalTrials.gov ↗

recruiting Neurology NCT05839418

Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)

SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults…

Sponsor: Erasme University Hospital

View Trial ClinicalTrials.gov ↗

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer’s Disease (ADEPT-3)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer’s Disease (ADEPT-1)

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson’s Disease

Longitudinal Assessment of Iron Rims in MS Lesions

Hesperidin RCT in MS

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)

Join 10,000+ UK Clinicians